Shield Therapeutics plc (STX) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.303x

Based on the latest financial reports, Shield Therapeutics plc (STX) has a cash flow conversion efficiency ratio of 0.303x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-4.49 Million ≈ $-546.85 USD) by net assets (GBX-14.86 Million ≈ $-1.81K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Shield Therapeutics plc stock valuation for the company's overall valuation and market capitalisation.

Shield Therapeutics plc - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Shield Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Shield Therapeutics plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Shield Therapeutics plc ranked by their cash flow conversion efficiency. Explore Shield Therapeutics plc (STX) cash earnings ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
OSX Brasil S.A SA:OSXB3	0.000x
Asian Television Network International Ltd V:SAT	-0.121x
DBT SA PA:ALDBT	-0.387x
Kuchai Develop Bhd KLSE:2186	-0.008x
Cora Gold Limited LSE:CORA	-0.013x
C3is Inc. NASDAQ:CISS	-0.015x
InsuraGuest Technologies Inc V:ISGI	0.216x
Ivory Properties Group Bhd KLSE:5175	0.629x

Annual Cash Flow Conversion Efficiency for Shield Therapeutics plc (2014–2024)

The table below shows the annual cash flow conversion efficiency of Shield Therapeutics plc from 2014 to 2024. View today's stock price for Shield Therapeutics plc for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	GBX-1.05 Million ≈ $-127.95	GBX-7.01 Million ≈ $-852.49	6.663x	+500.42%
2023-12-31	GBX22.31 Million ≈ $2.71K	GBX-37.13 Million ≈ $-4.52K	-1.664x	+50.51%
2022-12-31	GBX5.43 Million ≈ $660.31	GBX-18.25 Million ≈ $-2.22K	-3.362x	-724.25%
2021-12-31	GBX41.03 Million ≈ $4.99K	GBX-16.74 Million ≈ $-2.04K	-0.408x	-782.15%
2020-12-31	GBX30.28 Million ≈ $3.68K	GBX-1.40 Million ≈ $-170.34	-0.046x	+63.44%
2019-12-31	GBX32.15 Million ≈ $3.91K	GBX-4.07 Million ≈ $-494.71	-0.126x	-2773.01%
2018-12-31	GBX40.43 Million ≈ $4.92K	GBX-178.00K ≈ $-21.66	-0.004x	+98.88%
2017-12-31	GBX41.21 Million ≈ $5.01K	GBX-16.15 Million ≈ $-1.97K	-0.392x	-84.95%
2016-12-31	GBX48.40 Million ≈ $5.89K	GBX-10.26 Million ≈ $-1.25K	-0.212x	-194.45%
2015-12-31	GBX-18.64 Million ≈ $-2.27K	GBX-4.18 Million ≈ $-508.95	0.224x	+22.79%
2014-12-31	GBX-18.28 Million ≈ $-2.22K	GBX-3.34 Million ≈ $-406.50	0.183x	--

About Shield Therapeutics plc

LSE:STX UK Drug Manufacturers - Specialty & Generic

Market Cap

$617.24K

GBX5.07 Billion GBX

Market Cap Rank

#30962 Global

#894 in UK

Share Price

GBX4.75

Change (1 day)

+0.00%

52-Week Range

GBX3.70 - GBX12.20

All Time High

GBX185.02